Ramelteon combined with an $\alpha_1$-blocker decreases nocturia in men with benign prostatic hyperplasia

Takashi Kawahara1,2,5*, Satoshi Morita3, Hiroki Ito1,2, Hideyuki Terao1, Ryoko Sakata2, Hitoshi Ishiguro5, Katsuyuki Tanaka4, Hiroshi Miyamoto5, Junichi Matsuzaki1, Yoshinobu Kubota2 and Hiroji Uemura2*

Abstract

Background: Nocturia is defined as waking one or more times during the night due to the urge to void. Recently, the effectiveness of several sedatives and analgesics for nocturia has been reported. We herein investigated the effects of ramelteon, an antioxidant and sleep inducer, on nocturia unresponsive to $\alpha_1$-blocker monotherapy in males with lower urinary tract symptoms (LUTS) as a pilot study.

Methods: Subjects were 19 patients who had LUTS suggestive of benign prostate hyperplasia, received $\alpha_1$-blockers (tamsulosin, silodosin, or naftopidil), and continued to have two or more episodes of nocturia per night before starting ramelteon. Ramelteon at 8 mg once daily for one month was added to the $\alpha_1$-blocker. A self-administered questionnaire including the International Prostate Symptom Score (IPSS), quality of life (QoL) index, Overactive Bladder Symptom Score (OABSS), and Nocturia Quality-of-Life Questionnaire (N-QOL) were assessed before and one month after starting ramelteon.

Results: The mean score on IPSS question 7 (nocturia) decreased significantly from 2.88 before starting ramelteon to 2.41 one month after starting the medication ($P = 0.03$). The mean total OABSS decreased significantly from 6.31 to 5.38 ($P = 0.03$), and the mean for OABSS question 2 (nighttime frequency of nocturia) also significantly decreased from 2.63 to 2.13 ($P = 0.01$). The mean total N-QOL score did not change significantly. Two patients had dizziness; the remaining patients had no adverse drug-related events.

Conclusions: Ramelteon in combination with an $\alpha_1$-blocker could be a treatment option for reducing nocturia in men with BPH.

Keywords: Ramelteon, Melatonin, Nocturia, Benign prostate hyperplasia, $\alpha_1$-blocker

Background

Nocturia is defined by the International Continence Society as waking one or more times during the night because of the urge to void [1]. Nocturia is known to be related to many other diseases and conditions, including overactive bladder, benign prostate hyperplasia (BPH), obstructive sleep apnea and congestive heart failure [2]. Various other factors, including nighttime liquid, caffeine and alcohol intake can also result in an increased urinary volume at night and increased nocturia [3]. The timing of therapy with diuretics, beta-blockers and xanthines may also cause some people to void more frequently at night [4]. Middelkoop et al. described that nocturia and associated worries were the most frequent causes of disturbed sleep in adults over the age of 50 years [5]. Tsujimura et al. reported that urgency and nocturia are factors that independently affect sleep quality, which is closely related to patient quality of life [6]. Moreover, when nighttime waking occurs two or more times, nocturia has also been associated with a 10–21% increased risk of falling, limb fracture, excessive daytime somnolence, and nocturnal enuresis [7].

* Correspondence: takashi_tk2001@yahoo.co.jp; hu0428@med.yokohama-cu.ac.jp
1Department of Urology, Ohguchi Higashi General Hospital, Yokohama, Kanagawa, Japan
2Department of Urology, Yokohama City University Graduate School of Medicine, 3-9, Fukaura, Kanazawa-ku, Yokohama, Kanagawa, Japan
Full list of author information is available at the end of the article

© 2013 Kawahara et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Recently, the effectiveness of some sedatives and analgesics for nocturia has been reported [8]. Drake et al. reported the effectiveness of melatonin for nocturia in a randomized, double-blind, placebo-controlled crossover study in 20 men [9] Shimizu et al. reported that ramelteon significantly decreased the nocturia for patients who had both LUTS and insomnia [10]. Ramelteon, the first melatonin receptor agonist approved by the United States and Japan, is a selective MT1 and MT2 agonist, [11] and its efficacy and safety for chronic insomnia has been reported [12,13]. Here we investigated the effects of ramelteon, an antioxidant and sleep inducer in humans, on nocturia unresponsive to α1-blocker monotherapy in men with LUTS as a pilot study.

Methods
Subjects were 19 patients, with a median and mean (± standard deviation [SD]) age of 72.0 and 72.1±10.6 years, respectively. This study was approved by the Institutional Review Board of Ohguchi Higashi General Hospital, and written informed consent for participation was obtained from all patients. All patients with LUTS suggested of BPH who were taking an α1-adrenoceptor antagonist (tamsulosin, silodosin, or naftopidil) for more than 3months and experiencing two or more episodes of nocturia per night were examined before being administered ramelteon. None of the patients were taking a 5α-reductase inhibitor or anticholinergic drug. The exclusion criteria included prostate cancer, urinary tract infection, and stone disease. In this study, no patients had nocturnal polyuria or sleep disturbances. Ramelteon was taken at 8mg once daily (at bedtime) for 1month, in addition to the regular α1-blocker. The type of α1-blocker was not changed during the study period. A self-administered questionnaire including the International Prostate Symptom Score (IPSS), quality of life (QoL) index, Overactive Bladder Symptom Score (OABSS), and Nocturia Quality-of-Life Questionnaire (N-QOL) were assessed before and 1month after starting ramelteon (Additional files 1, 2, 3 and 4). The IPSS is most commonly used as an assessment tool for men with BPH or OAB, or for those who have undergone radical prostatectomy or prostatic radiotherapy [14-17]. The IPSS questionnaire comprises seven questions on LUTS (incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia) and an additional question to yield a QoL index, ranging from zero (delighted) to six (terrible), which was used as the QoL surrogate indicator in this study. OAB is defined as a symptom syndrome that includes urgency, with or without urgency incontinence, and usually with frequency and nocturia [18]. N-QOL is a method for measuring treatment impact on sleep quality and on QoL thorough the evaluation of any treatment of nocturia [19].

Statistical analysis
All continuous variables are expressed as median and mean ± SD values. Numerical data were compared using the Wilcoxon Signed Rank Sum test. An analysis of the difference in the number of patients with nocturia before and after treatment was performed using McNemar’s test. A P-value of 0.05 or less was considered significant.

Results
Table 1 shows patient data including the type of α1-blocker taken and other baseline characteristics including age, prostate volume, serum prostate specific antigen (PSA) levels, and data of uroflowmetry. The data were distributed normally. In this study, no differences were noted in age, past history or medication use between the patients who were likely to respond and those who were not. There was also no significant difference in nocturia at baseline between patients taking tamsulosin silodosin and naftopidil. Five patients had hypertension with antihypertension drugs, three had diabetes mellitus with anti diabetes mellitus drugs, and three had a medication of a diuretic. None of the patients who were medicated with diabetes mellitus drugs had neurogenic conditions.

After 1 month of taking ramelteon, mean score on IPSS question 7 (nocturia) showed improvement, decreasing significantly from 2.88 ± 0.70 to 2.41 ± 1.00 (P = 0.03). However, total IPSS and QoL score did not change significantly (Table 2). Mean total OABSS also improved, decreasing significantly from 6.31 ± 2.15 to 5.38 ± 2.16 (P = 0.03), and likewise mean OABSS for question 2 (nighttime frequency of nocturia) decreased significantly from 2.63 ± 0.50 to 2.13 ± 0.62 (P = 0.01; Table 3). The mean total N-QOL score did not change significantly.

Table 1 Patient characteristics

| Variables                          | Number (%) or Median (mean±SD) |
|-----------------------------------|---------------------------------|
| No. of patients                   | 19                              |
| Age, years                        | 72.0 (72.1 ± 10.6)              |
| Prostate vol, mL                   | 37.3 (41.9 ± 25.3)              |
| Serum PSA, ng/mL                   | 3.6 (4.7 ± 4.1)                 |
| Uroflowmetry                       |                                 |
| Peak flow rate, mL/s              | 10.5 (13.2 ± 10.0)              |
| Average flow rate, mL/s           | 5.0 (7.1 ± 5.5)                 |
| Residual volume, mL               | 20.0 (20 ± 21.8)                |
| Type of alpha-1-adrenergic antagonists (blockers) | |
| Tamsulosin (0.2 mg/day)           | 8 (42.1%)                       |
| Silodosin (8 mg/day)              | 2 (10.5%)                       |
| Naftopidil (75 mg/day)            | 9 (47.4%)                       |

Type of alpha-1-adrenoceptor antagonists (blockers)
However, N-QOL scores for questions 2 (Low in energy the next day) and 6 (Careful about drinking water) showed improvement, decreasing significantly from 1.60 ± 1.30 to 1.13 ± 0.99 (P = 0.048) and 2.20 ± 1.52 to 1.73 ± 1.28 (P = 0.0480), respectively (Table 4). There were no differences between the types of alpha-blockers in terms of the effectiveness against nocturia. A total of 13 patients (63.2%) exhibited a decrease in the number of nocturia episodes by more than one time. Nine (47.3%) patients exhibited nocturia one or fewer times per night. (p <0.01). A total of 16 patients (84.2%) wished to continue taking ramelteon because they felt that their urinary pattern was more convenient than before. On the other hand, three patients (15.8%) did not want to continue taking ramelteon because they felt that there had been no changes after adding ramelteon to their medications. Because of the small sample size in this study, we could not predict the patients who were likely to respond to ramelteon.

Two patients developed dizziness within a few days after starting ramelteon therapy; however, both patients recovered from dizziness within three to five days without discontinuing ramelteon. The remaining patients had no adverse drugs-related events.

**Discussion**

We evaluated the impact of ramelteon on nocturia in patients with BPH taking an α1-blocker. BPH can induce bladder outlet obstruction and cause secondary bladder overactivity and a diminution of functional bladder capacity, the last two of which may result in storage symptoms including nocturia [20]. α1-blockers are the most common treatment for lower urinary tract symptoms (LUTS) in men because they relax prostate smooth muscle and decrease urethral resistance [21]. All currently available α1-blockers have similar efficacy and improve symptoms by approximately 35% and maximum urinary flow rate by 1.8–2.5 mL/s. [21] α1-blockers have been shown most effective in treating LUTS associated with BPH [22-24]. Nocturia is one of the LUTS, and a variety of factors can contribute to nocturia, including polyuria, nocturnal polyuria, sleep disorder, medication, bladder storage disorder (BPH, OAB, interstitial cystitis, etc.), and advanced age [25]. In addition, medical and surgical treatment for nocturia has been reported to be less satisfactory than treatment of other LUTS [8,26]. The effectiveness of hypnotic or non-steroidal anti-inflammatory drugs has been reported; however, such drugs have positional side effects including affinity for benzodiazepine which is associated with adverse effects on cognitive function with the potential for abuse, dyspepsia, and nephropathy. For ramelteon on the other hand, both safety with chronic insomnia have been reported in Japanese patients [12,13,27]. Therefore, we selected ramelteon for the BPH patients with nocturia. In this study, however, uroflowmetry findings after treatment were only checked in three patients, and no differences were found.

Nocturia is assessed in IPSS question 7, the mean score of which decreased significantly from 2.88 to 2.41 (Table 2). Table 3 Pre and post OABSS

| Variables | Median (mean±SD) | P value |
|-----------|-----------------|---------|
| Q1        | 1 (1.9 ± 2.0)   | 1 (1.6 ± 1.7) | 0.631 |
| Q2        | 3 (2.8 ± 1.4)   | 2 (2.3 ± 1.3) | 0.263 |
| Q3        | 1 (1.9 ± 2.1)   | 1 (1.3 ± 1.3) | 0.603 |
| Q4        | 2 (1.8 ± 1.6)   | 1 (1.6 ± 1.5) | 0.227 |
| Q5        | 1 (1.6 ± 1.6)   | 1 (2.2 ± 1.9) | 0.598 |
| Q6        | 0 (1.1 ± 1.5)   | 1 (1.2 ± 1.6) | 0.756 |
| Q7        | 3 (2.9 ± 0.7)   | 2 (2.4 ± 1.0) | 0.033* |
| total score Q1-7 | 15 (15.0 ± 7.9) | 11 (12.6 ± 6.0) | 0.142 |
| QOL       | 5 (4.4 ± 1.5)   | 4 (3.8 ± 1.5) | 0.206 |

*; p < 0.05.

Table 4 Pre and post NQOL score

| Variables | Median (mean±SD) | P value |
|-----------|-----------------|---------|
| Q1        | 1 (1.1 ± 1.2)   | 1 (1.5 ± 1.2) | 0.280 |
| Q2        | 2 (1.6 ± 1.3)   | 1 (1.1 ± 1.0) | 0.048* |
| Q3        | 2 (1.3 ± 1.1)   | 1 (1.1 ± 1.2) | 0.531 |
| Q4        | 1 (1.1 ± 1.3)   | 1 (1.0 ± 0.8) | 0.709 |
| Q5        | 1 (1.6 ± 1.6)   | 0 (0.9 ± 1.2) | 0.077 |
| Q6        | 2 (2.2 ± 1.5)   | 2 (1.7 ± 1.3) | 0.048* |
| Q7        | 2 (2.2 ± 1.4)   | 1 (1.6 ± 1.0) | 0.070 |
| Q8        | 1 (0.7 ± 0.9)   | 1 (1.1 ± 1.2) | 0.136 |
| Q9        | 1 (1.5 ± 1.5)   | 1 (1.4 ± 1.3) | 0.806 |
| Q10       | 3 (2.2 ± 1.5)   | 3 (2.3 ± 1.3) | 0.653 |
| Q11       | 3 (2.3 ± 1.5)   | 3 (2.4 ± 1.2) | 0.634 |
| Q12       | 3 (2.3 ± 1.4)   | 2 (2.1 ± 1.1) | 0.510 |
| Q13       | 4 (4.5 ± 3.1)   | 3 (4.1 ± 2.7) | 0.604 |
| total score | 23 (24.7 ± 14.6) | 23 (22.4 ± 12.3) | 0.434 |

*; p < 0.05.
(P = 0.03) after participants in this study took ramelteon for 1 month. However, the impact of nocturia may not be fully captured by the IPSS questionnaire alone. Chapple et al. reported that the IPSS does not show how nocturia decreases sleep quality or how decreasing sleep quality affects QoL [19]. Therefore, a thorough evaluation of any treatment of nocturia requires the use of a method to measure the treatment impact on sleep quality and the QoL [19]. The International Consultation on Incontinence Questionnaire (ICIQ) N-QOL instrument, developed by Abraham et al., is an easily administered, self-completed questionnaire that specifically assesses the impact of nocturia on the QoL [28]. In 2009, Yoshida et al. validated a Japanese version of the N-QOL. In the present study, the total score on the Japanese N-QOL did not change significantly with ramelteon, but the mean scores for questions 2 (Low in energy the next day) and 6 (Careful about drinking water) did. Question 2 might be related to the pharmacological effect of ramelteon’s association with circadian rhythm. Melatonin is currently the most accurate marker of human circadian pacemaker activity [29]. With regard to the clinical guidelines for nocturia, most patients with nocturia were coached by lifestyle guidance and behavioral therapy including “Careful about water intake”, which is the same question of N-QOL Q6 issued by urologists [25]. As a result of decreased nocturia, we speculate that patients were not concerned about drinking water.

The OABSS, originally developed in Japan, is a 4-item questionnaire to express OAB symptoms on a single scale [30]. The OABSS question items address individual symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Gotoh et al. reported that OABSS is a useful tool for assessing the effects of treatment on OAB symptoms and responsive to treatment-related changes [31]. In the present study, total score and the score of nighttime frequency (OABSS question 2) decreased significantly (P = 0.01, 0.027 respectively).

Yun et al. reported that zolpidem combined with an α1-blocker was associated with decreased nocturia. Kaye et al. reported that oxazepam and naproxen, among five different sedatives and analgesics, significantly decreased nocturia [17]. Shimizu et al. reported that ramelteon decreased nocturia in a cohort of 49 patients, including patients with insomnia with prostate cancer and BPH, and those who had undergone radical prostatectomy [10]. The number of nocturia episodes was decreased from 3.1 to 2.2 per night in that study (P < 0.001). Our results support these data. The authors of that study also showed that ramelteon increased the nighttime bladder capacity from 181.4 to 201.1 cc (P < 0.05) [10]. A randomized study to confirm the effectiveness of ramelteon is needed. In the Japanese general population, the prevalence of insomnia was calculated to be about 20% and 30% in individuals aged 60 years and older [32,33]. Among widely used drugs, benzodiazepine receptor agonists exert their hypnotic effects through binding to the gamma-aminobutyric acid (GABA)-a receptor complex in the brain [34]. However, this mechanism of action of the benzodiazepines can lead to impairments in cognitive and psychomotor functions and increase the potential for dependence and withdrawal symptoms, including rebound insomnia [34]. Zopiclone also binds to GABAa receptors but differs from the benzodiazepines in the subtype of receptor it binds [25,26]. Moreover, it has a similar efficacy but is associated less frequently with next-day sedation and carries a lower risk of dependence [34,35].

Melatonin is a neurohormone secreted by the pineal gland that is involved in regulating the sleep-wake cycle and circadian rhythm [36]. Drake et al. reported the effectiveness of melatonin for nocturia in a randomized, double-blind, placebo-controlled crossover study in 20 men [9]. Its secretion is regulated by the suprachiasmatic nucleus, and the melatonin MT1 and MT2 receptors appear to be involved in sleep onset, while MT2 receptors mediate the phase-shifting effect of melatonin on circadian rhythm [12]. Ramelteon, the first melatonin receptor agonist approved for the treatment of insomnia in the United States and Japan, is an MT1 and MT2 agonist and has a 3- to 5-fold greater affinity for these receptors than melatonin [11]. However, ramelteon has no significant affinity for the MT3 receptor, which is located outside of the central nervous system and is not thought to be involved with sleep/circadian rhythms [11]. Ramelteon has no significant affinity for benzodiazepine, dopamine, or opiate receptors, sites that have been associated with adverse effects on cognitive function and carry the potential for abuse [11].

Melatonin is safe in older adults and reported adverse effects are infrequent, although little is known about long term use or drug interactions [9,37]. Documented side effects include decreases in body temperature, sedation, headache, depression, tachycardia, and pruritus. In our study, 2 of 19 (11%) participants experienced dizziness. Uchiyama et al. reported long-term safety and efficacy of ramelteon treatment for chronic insomnia [13].

This study had some limitations including the small sample size and the assessment over the short-term of only one dosage schedule of ramelteon. Previous reports have shown that naftopidil improves nocturia [38]. In the present study, all patients had received naftopidil. Eight patients in the tamsulosin group and two patients in the silodosin group had received naftopidil at some stage. These patients had not been satisfied with the effects of naftopidil. Therefore, they were switched to the another alpha-blocker. These findings suggest that ramelteon may be effective for patients who are resistant to naftopidil. In
addition, we did not investigate bladder outflow obstruction using urodynamic study because of invasive examination. As such, this study provides a useful initial evaluation of ramelteon in combination with an α1-blocker for the treatment of nocturia. Because this study confirmed a lack of severe side effects of the treatment, we are now conducting a multicenter, randomized study of ramelteon for nocturia.

Conclusions
Our results showed that ramelteon in combination with an α1-blocker could be a new option for reducing nocturia in men with BPH.

Additional files

Additional file 1: International Prostate Symptom Score (IPSS).
Additional file 2: Overactive bladder symptom score (OABSS).
Additional file 3: International Prostate Symptom Score (IPSS) Japanese version.
Additional file 4: Overactive bladder symptom score (OABSS) Japanese version.

Competing interest
All authors declare that they have no competing interests.

Authors’ contributions
TK, HI, HT, RS, KT and JM obtained the data. TK and SM participated in designing of the study and performed the statistical analysis. TK and HU wrote the draft the manuscript. HI, HM, HU and YK analyzed the data. All authors read and approved the final manuscript.

Funding
Aid for Young Medical Scientists from Yokohama Foundation for Advancement of Medical Science.

Author details
1Department of Urology, Ohguchi Higashi General Hospital, Yokohama, Kanagawa, Japan. 2Department of Urology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan. 3Department of Biostatistics and Epidemiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 4Department of Urology, Kanagawa Rehabilitation Hospital, Atsugi, Kanagawa, Japan. 5Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.

Received: 10 March 2013 Accepted: 4 June 2013 Published: 12 June 2013

References
1. van Kerrebroeck P, Abrams P, Chakkin D, Donovan J, Fonda D, Jackson S, Jennun P, Johnson T, Lose G, Mattiasson A, et al: The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21(2):179–183.
2. Johnson TM 2nd, Markland AD, Goode PS, Vaughan CP, Colli JL, Oudlande JG, Redden DT, McGewin G, Burgio KL. Efficacy of adding behavioural treatment or antimuscarinic drug therapy to alpha-blocker therapy in men with nocturia. BJU Int 2013, 112(3):397–402.
3. Weiss JPBI: Nocturnal polyuria versus overactive bladder in nocturia. Urology 2002, 60(Suppl 1):S8–12.
4. Appel RASP: Nocturia: etiology, diagnosis, and treatment. Neurourol Urodyn 2008, 27(1):34–39.
5. Middelkoop HA, den Doel DA S-v, Neven AK, Kamphuisen HA, Springer CP: Subjective sleep characteristics of 1,485 males and females aged 50–93: effects of sex and age, and factors related to self-evaluated quality of sleep. J Gerontol A Biol Sci Med Sci 1996, 51(3):M108–M115.
6. Tsujimura A, Takao T, Miyagawa Y, Yamamoto K, Fukuhara S, Nakayama J, Kuchi H, Suganuma N, Nakamura T, Kumanogoo T, et al: Urgency is an independent factor for sleep disturbance in men with obstructive sleep apnea. Urology 2010, 76(4):967–970.
7. Kim SO, Choi HS, Kim YJ, Kim HS, Hwang EC, Oh KJ, Jung SI, Kang TW, Kwon D, et al: Impact of nocturia on health-related quality of life and medical outcomes study sleep score in men. Int J Neurosci 2011, 15(2):82–86.
8. Kaye M: Nocturia: a blinded, randomized, parallel placebo-controlled self-study of the effect of 5 different sedatives and analgesics. Can Urol Assoc J 2008, 2(6):604–608.
9. Drake MJ, Mills IW, Noble, JG. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol 2004, 171(3):1195–1202.
10. Shirizu NS, Nozawa M: Efficacy of ramelteon in patients with insomnia and nocturia. JUTS 2012. doi:10.1111/j.1757-5672.2012.01660.x. Epub ahead of print.
11. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hiruma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005, 48(6):301–310.
12. Uchijama M, Harnamura M, Kuvano T, Nishiyama H, Nagata H, Uchimura N: Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med 2011, 12(2):119–126.
13. Uchijama M, Harnamura M, Kuvano T, Nagata H, Hashimoto T, Ogawa A, Uchimura N: Long-term safety and efficacy of ramelteon in Japanese patients with chronic insomnia. Sleep Med 2011, 12(2):127–133.
14. Barry MJ, Williford WO, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Nebust WK, Cockett AT: The American Urological Association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol 1992, 148(5):1549–1557.
15. Chapple C, Henschorn S, Abrams P, Sun F, Brodsky M, Guan Z: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009, 56(3):334–341.
16. Moore KN, Valiquette L, Chetner MP, Bymalik S, Herbison GP: Return to continent after radical retroperitoneal prostatectomy: a randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. Urology 2008, 72(6):1280–1286.
17. Keyes M, Miller S, Moravan V, Pickles T, McKenzie M, Pali H, Liu M, Kwan W, Agranovich A, Spadinger I, et al: Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2009, 73(4):1023–1032.
18. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international Continence Society. Urology 2002, 61(3):37–40.
19. McIlveen MC, Chapple CR: Comparison of the cardiovascular and neurochemical properties of ramelteon (TAK-375) with those of zolpidem (D 50955). J Med Chem 2000, 43(1):1557–1561.
20. Homma Y, Araki I, Igawa Y, Ozono S, Gotoh M, Yamanishi T, Yokoyama O, Yoshimura M, Arai Y: Nocturia and benign prostatic hyperplasia. Urol Int 2003, 64(3):786–790.
21. Schwinn DA, Roehrborn CG: Alpha-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008, 15(3):193–199.
22. Brawer MK, Lin DW, Willford WO, Jones K, Lepor H: Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate 1999, 39(4):234–239.
23. Homma Y, Araki I, Igawa Y, Ozono S, Gotoh M, Yamanishi T, Yokoyama O, Yoshimura M: Clinical guideline for male lower urinary tract symptoms. Int J Urol 2009, 16(10):775–790.
24. McVary KT, Roehrborn CG, Asimakopoulou A, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF, et al: Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011, 185(5):1793–1803.
25. Committee for Establishment of the Clinical Guidelines for Nocturia of the Neurogenic Bladder Society:: Clinical guidelines for nocturia. Int J Urol 2010, 17(5):397–400.
26. Bruskewitz RC, Larsen EH, Madsen PO, Dorflinger T: Night-time urine production. J Urol 1986, 136(3):615–618.
27. Okada S, Watanabe H, Kojima Y, Yanai Y, Sasaki S, Kohk K: Loxoprofen sodium treatment for elderly men with refractory nocturia: effect on night-time urine production. Int J Urol 2008, 15(5):462–464.
28. Abraham L, Hareendran A, Mills IW, Martin ML, Abrams P, Drake MJ, MacDonagh RP, Noble JG: Development and validation of a quality-of-life measure for men with nocturia. *Urology* 2004, 63(3):481–486.

29. Klerman H, St Hilaire MA, Kronauer RE, Gooley JJ, Gronfier C, Hull JT, Lockley SW, Santhi N, Wang W, Klerman EB: Analysis method and experimental conditions affect computed circadian phase from melatonin data. *PLoS One* 2012, 7(4):e33836.

30. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O: Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. *Urology* 2006, 68(2):318–323.

31. Gotoh M, Homma Y, Yokoyama O, Nishizawa O: Responsiveness and minimal clinically important change in overactive bladder symptom score. *Urology* 2011, 78(4):768–773.

32. Kim K, Uchiyama M, Okawa M, Liu X, Ogihara R: An epidemiological study of insomnia among the Japanese general population. *Sleep* 2000, 23(1):41–47.

33. Liu X, Uchiyama M, Kim K, Okawa M, Shibui K, Kudo Y, Doi Y, Minowa M, Ogihara R: Sleep loss and daytime sleepiness in the general adult population of Japan. *Psychiatry Res* 2000, 93(1):1–11.

34. Ramakrishnan K, Scheid DC: Treatment options for insomnia. *Am Fam Physician* 2007, 76(4):517–526.

35. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M: The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. *J Gen Intern Med* 2007, 22(9):1335–1350.

36. Doghramji K: Melatonin and its receptors: a new class of sleep-promoting agents. *J Clin Sleep Med* 2007, 3(5 Suppl):S17–S23.

37. Nowak JZ, Zawilska JB: Melatonin and its physiological and therapeutic properties. *Pharm World Sci* 1998, 20(1):18–27.

38. Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T: Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. *Int J Urol* 2006, 13(1):15–20.

doi:10.1186/1471-2490-13-30
Cite this article as: Kawahara et al.: Ramelteon combined with an α-blocker decreases nocturia in men with benign prostatic hyperplasia. *BMC Urology* 2013, 13:30.